All In Biotech

Drug Trial Radar · NCT05580588

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

14

Actual

Start

Aug 31, 2023

Primary completion

Oct 4, 2024

Study completion Oct 31, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with specific types of liposarcomas (tumors expressing the target of the study drug).

Conditions

  • Liposarcoma, Dedifferentiated

Interventions

  • SPH4336Drug

    400 mg SPH4336 PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) at 12 WeeksTime frame: 12 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • University of Michigan

    Ann Arbor, Michigan

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Seidman Cancer Center, University Hospitals

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.